DiaMedica to Present Results of Monoclonal Antibody for Type 2 Diabetes at the Biennial IDF World Diabetes Congress Conference

WINNIPEG, MANITOBA--(Marketwire - Sept. 19, 2011) - DiaMedica (TSX VENTURE:DMA) today announces that it has been invited to present its late-breaking abstract for a poster and presentation covering results of pre-clinical studies of DM-204 for the treatment of Type 2 diabetes. The material will be presented on December 5, 2011 at the 21^st biennial World Diabetes Congress organized by the International Diabetes Federation (IDF) in Dubai, United Arab Emirates.

The poster and presentation is titled "Novel DM-204 monoclonal antibody triggers insulin secretion, insulin sensitivity and reduction in blood pressure." The Company previously released high-level results that animals acutely treated with DM-204 demonstrated a 291% increase in maximal glucose infusion rate (p >0.0035) measured in the hyperinsulinemic euglycemic clamp model. In a separate study, DM-204 lowered systolic blood pressure by 15 mmHg (p <0.05).

"We look forward to sharing the exceptional results of our DM-204 Type 2 diabetes program at the IDF World Diabetes Congress that is expected to draw more than 15,000 participants and is one of the largest and most important healthcare conferences in the world", stated Dr. Mark Williams, Vice President of Research at DiaMedica who will be presenting the results of DiaMedica's novel monoclonal antibody to treat both Type 2 diabetes and one of its major complications, high blood pressure.

About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic compounds aimed to improve the lives of patients with diabetes and other major, medically-unmet diseases. DiaMedica's lead compound, DM-199, represents a novel approach to treating Type 1 and Type 2 diabetes by demonstrating significant results against three major aspects of these diseases: 1) halting the autoimmune attack on beta cells; 2) proliferating insulin producing beta cells and 3) improving glucose control.

DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the enzyme glycogen synthase kinase 3 beta (GSK3B). In preclinical studies, DM-204 significantly improved glucose control and decreased blood pressure.

The company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

Caution Regarding Forward-Looking Information

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.